Citeline, Biomedtracker: see the drug development process th...
Catch up on any missed COVID-19 24 hour webinar sessions
As the aging population in the US, UK and Europe increases, cases of multiple have increased as well, bring new therapies and questions about the future of care. This webinar provides a comprehensive look at the disease and treatments including the new launches that are transforming clinical practice, the relative value of multiple myeloma regimens, and the evolution of the multiple myeloma market.
Beginning with the current access levers used by payers and a comparison of US and five major European markets, you’ll learn the key factors in European payers’ assessment of multiple myeloma treatments, the significant changes we are seeing in the US oncology market, and why payers have begun imposing cost-control strategies such as ICER and other value frameworks to evaluate cost-effectiveness.
Datamonitor Healthcare: data analysis and insight, Pink Shee...
By Tara Hansen
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.
Datamonitor Healthcare: data analysis and insight
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: